Evidence map›Paper›PMID 33338398›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2021

Therapeutic Targeting of PTEN in Duchenne Muscular Dystrophy.

Arshiya Parveen, Yefei Wen, Anirban Roy, Ashok Kumar

Open access · hybridAbstract readComment
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. miRNA dysregulation in Duchenne muscular dystrophy comorbidities.World journal of experimental medicine · 2025
    Article
  2. Article
  3. Review
  4. Emerging role of TAK1 in the regulation of skeletal muscle mass.BioEssays : news and reviews in molecular, cellular and developmental biology · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Arshiya ParveenDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Yefei WenDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Anirban RoyDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Ashok KumarDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX 77204, USA. Electronic address: akumar43@central.uh.edu.
University of Houston · US

Funding

TAK1/TRAF6 Signaling in Skeletal MuscleR01AR059810 · NIAMS · UNIVERSITY OF LOUISVILLE · PI KUMAR, ASHOK · 2011 to 2021
$4.0M
MYD88 Signaling in Mammalian Myoblast FusionR01AR068313 · NIAMS · UNIVERSITY OF LOUISVILLE · PI KUMAR, ASHOK · 2015 to 2019
$1.7M
NIAMS NIH HHS R01 AR059810NIAMS NIH HHS R01 AR068313
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Muscular Dystrophy, DuchenneAnimalsMiceMusclesMuscular Atrophy

Identifiers

PMID33338398
PMCPMC7791074
OpenAlexW3116068861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.